ADMINISTRATIVE RULES Fiscal Estimate & Economic Impact Analysis

1. Type of Estimate and Analysis ⊠ Original □ Updated □Corrected	2. Date 10/7/2020	
3. Administrative Rule Chapter, Title and Number (and Clearinghouse Number if applicable) CSB 2.67		
4. Subject Scheduling of brexanolone and solriamfetol.		
5. Fund Sources Affected	6. Chapter 20, Stats. Appropriations Affected	
7. Fiscal Effect of Implementing the Rule ☑ No Fiscal Effect ☐ Increase Existing Revenues ☐ Indeterminate ☐ Decrease Existing Revenues	□ Increase Costs □ Decrease Costs □ Could Absorb Within Agency's Budget	
Local Government Units Publi	ific Businesses/Sectors c Utility Rate Payers I Businesses (if checked, complete Attachment A)	
9. Estimate of Implementation and Compliance to Businesses, Local Governmental Units and Individuals, per s. 227.137(3)(b)(1). \$0.00		
 10. Would Implementation and Compliance Costs Businesses, Local Governmental Units and Individuals Be \$10 Million or more Over Any 2-year Period, per s. 227.137(3)(b)(2)? ☐ Yes ☐ No 		
11. Policy Problem Addressed by the Rule The United States Department of Justice, Drug Enforcement Administration scheduled brexanolone and solriamfetol as schedule IV controlled substances effective June 17, 2019. The Wisconsin Controlled Substances Board took affirmative action on July 17, 2019 to similarly treat brexanolone and solriamfetol under chapter 961 effective July 22, 2019 to allow for publication in the Administrative Register. The Board is currently promulgating a final rule.		
 Summary of the Businesses, Business Sectors, Associations Representing Business, Local Governmental Units, and Individuals that may be Affected by the Proposed Rule that were Contacted for Comments. This rule was posted for economic comments and none were received. 		
13. Identify the Local Governmental Units that Participated in the Development of this EIA. None		
 14. Summary of Rule's Economic and Fiscal Impact on Specific Businesses, Business Sectors, Public Utility Rate Payers, Local Governmental Units and the State's Economy as a Whole (Include Implementation and Compliance Costs Expected to be Incurred) This rule schedules brexamolone and solriamfetol and does not have an economic or fiscal impact on businesses or the State's economy as a whole. 		
15. Benefits of Implementing the Rule and Alternative(s) to Implementing the Rule The benefit is for the federal and state controlled substances acts to be in conformity and alleviate confusion. In addition, it is in the best interest of Wisconsin citizens to schedule brexanolone and solriamfetol as schedule IV controlled substances.		
16. Long Range Implications of Implementing the Rule Brexanolone and solriamfetol will be treated as a schedule IV controlled substances.		

17. Compare With Approaches Being Used by Federal Government

ADMINISTRATIVE RULES Fiscal Estimate & Economic Impact Analysis

The federal government has scheduled brexanolone and solriamfetol as a schedule IV controlled substances.

18. Compare With Approaches Being Used by Neighboring States (Illinois, Iowa, Michigan and Minnesota) Iowa has scheduled brexanolone and solriamfetol as Schedule IV controlled substances. Illinois, Michigan and Minnesota have not scheduled brexanolone or solriamfetol.

19. Contact Name	20. Contact Phone Number
Sharon Henes	(608) 261-2377

This document can be made available in alternate formats to individuals with disabilities upon request.

ADMINISTRATIVE RULES Fiscal Estimate & Economic Impact Analysis

ATTACHMENT A

1. Summary of Rule's Economic and Fiscal Impact on Small Businesses (Separately for each Small Business Sector, Include Implementation and Compliance Costs Expected to be Incurred)

2. Summary of the data sources used to measure the Rule's impact on Small Businesses

- 3. Did the agency consider the following methods to reduce the impact of the Rule on Small Businesses?
- Less Stringent Compliance or Reporting Requirements
- Less Stringent Schedules or Deadlines for Compliance or Reporting
- Consolidation or Simplification of Reporting Requirements
- Establishment of performance standards in lieu of Design or Operational Standards
- Exemption of Small Businesses from some or all requirements

Other, describe:

4. Describe the methods incorporated into the Rule that will reduce its impact on Small Businesses

- 5. Describe the Rule's Enforcement Provisions
- 6. Did the Agency prepare a Cost Benefit Analysis (if Yes, attach to form)

🗌 Yes 🗌 No